Alzheimer’s Awareness Month: What Accel is doing to help now and in the future - Accel Research Sites

Create a Profile

I accept digital forms of communication(Required)
Hidden
Hidden
This field is for validation purposes and should be left unchanged.

Create a Profile

I accept digital forms of communication(Required)
Hidden
Hidden
This field is for validation purposes and should be left unchanged.

Get In Touch Mobile

I accept digital forms of communication(Required)
This field is for validation purposes and should be left unchanged.

FIND A TRIAL NEAR YOU

No location found for this Zip Code

-- or --

No location found for this Location

FIND A TRIAL NEAR YOU

No location found for this Zip Code

-- or --

No location found for this Location
Back
Date Published: 11/15/2021

Alzheimer’s Awareness Month: What Accel is doing to help now and in the future

The disease will progress, with symptoms ranging from memory loss to the inability to respond.

There is no cure. Indeed, according to the Alzheimer’s Association, Alzheimer’s is the sixth leading cause of death in the United States. A person on average lives 4 to 8 years after diagnosis. At Accel Research Sites, we hope to change that.

November is Alzheimer’s Awareness Month, so this month, we wanted to tell you about our work on Alzheimer’s Disease clinical trials, which we are incredibly passionate about.

Accel Research Sites has several locations that specialize in neurology and psychiatry and are particularly suited for the study of Alzheimer’s-related treatments and drugs.

Principal investigators who have conducted Alzheimer’s research include:

  • Dr. Bruce Rankin in DeLand, Florida
  • Dr. Eva-Maria Heurich in Maitland, Florida
  • Dr. James Andersen in Lakeland, Florida
  • Dr. Deborah Burke in Tampa, Florida
  • Dr. Gigi Lefebvre in St. Petersburg, Florida
  • Dr. Marshall Nash in Decatur, Georgia

These doctors have conducted a wide variety of Alzheimer’s clinical trials, including those aimed at early onset dementia and those aimed at Alzheimer’s Disease with Agitation. In fact, we recently concluded a trial aimed at those dealing with Alzheimer’s Disease with Wandering.

One very exciting trial we recently started enrolling for is the Green Memory trial, led for Accel by Dr. Nash in Decatur and Dr. Burke in Tampa. The study is testing Sodium Oligomannate’s ability to improve patient’s cognitive scores, rather than to simply slow the disease’s effects. Accel was one of the leading enrollers in the study worldwide.

We’re passionate about all of our clinical research because we’re excited about moving medicine forward with each new advancement—but with Alzheimer’s Disease, it hits home even more. We know what a difference treatment—and one day, we hope, a cure—makes for the families dealing with this disease. For us, however, it’s not just about the moment a drug is FDA approved and available.

We see the difference clinical trials make for these patients and their loved ones, too. We are proud to be able to offer the very latest in potential treatment options to patients while it can make a huge difference for them through clinical trials.

That gives us—and our providers and patients—hope, both in Alzheimer’s Awareness Month and beyond.

If you or someone you love is interested in an Alzheimer’s clinical trial, please fill out this form on our website. A member of our staff will gladly get back to you for further qualification.

Back

Ready to be part of healthcare history? Find the right clinical trial for you.

Get In Touch

I accept digital forms of communication(Required)
This field is for validation purposes and should be left unchanged.
Accessibility Adjustment

Color Adjustment

Orientation Adjustment

Font Size

 

Line height